Tearsheet

Agios Pharmaceuticals (AGIO)

Market Price (4/12/2026): $32.93 | Market Cap: $1.9 Bil
Sector: Health Care | Industry: Biotechnology

Agios Pharmaceuticals (AGIO)

Market Price (4/12/2026): $32.93
Market Cap: $1.9 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -42%

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 48%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -32%

Megatrend and thematic drivers
Megatrends include Precision Medicine. Themes include Targeted Therapies, Biopharmaceutical R&D, and Personalized Diagnostics.

Weak multi-year price returns
2Y Excs Rtn is -11%, 3Y Excs Rtn is -14%

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -472 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -874%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 97%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -690%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -717%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -26%

Key risks
AGIO key risks include [1] make-or-break regulatory and clinical outcomes for its lead drug PYRUKYND, Show more.

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -42%
1	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 48%
2	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -32%
3	Megatrend and thematic drivers Megatrends include Precision Medicine. Themes include Targeted Therapies, Biopharmaceutical R&D, and Personalized Diagnostics.
4	Weak multi-year price returns 2Y Excs Rtn is -11%, 3Y Excs Rtn is -14%
5	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
6	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -472 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -874%
7	Significant share based compensation SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 97%
8	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -690%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -717%
9	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -26%
10	Key risks AGIO key risks include [1] make-or-break regulatory and clinical outcomes for its lead drug PYRUKYND, Show more.

Valuation, Metrics & Events

	4/12/26	2025	2024	2023	2022
Share Price CYE	$32.93	$29.30	$29.24	$22.97	$29.11
Market Cap CYE ($ Bil)	1.9	1.7	1.6	1.3	1.6
Total Debt ($ Bil)	0.0	0.1	0.1	0.1	0.1
Total Cash ($ Bil)	0.9	0.9	0.6	0.7	0.9
Enterprise Value ($ Bil)	1.1	1.8	1.7	1.4	1.7
Valuation Ratios
P/S TTM	35.6	45.5	56.1	66.8	1,908.8
P/EBIT TTM	-4.1	-3.8	-4.2	-3.4	-4.1
P/E TTM	-4.7	2.5	-4.7	-5.8	-4.4
P/FCF TTM	-5.0	-4.2	-5.2	-4.1	-4.1
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1	4.3	6.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7	-1.3	-2.2
P/E TTM (Sector)	-1.8	-1.3	-2.0	-1.5	-2.2
P/FCF TTM (Sector)	-1.7	-1.2	-2.0	-1.5	-2.5

	4/12/26	2025	2024
Share Price CYE	$32.93	$29.30	$29.24
Market Cap CYE ($ Bil)	1.9	1.7	1.6
Total Debt ($ Bil)	0.0	0.1	0.1
Total Cash ($ Bil)	0.9	0.9	0.6
Enterprise Value ($ Bil)	1.1	1.8	1.7
Valuation Ratios
P/S TTM	35.6	45.5	56.1
P/EBIT TTM	-4.1	-3.8	-4.2
P/E TTM	-4.7	2.5	-4.7
P/FCF TTM	-5.0	-4.2	-5.2
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7
P/E TTM (Sector)	-1.8	-1.3	-2.0
P/FCF TTM (Sector)	-1.7	-1.2	-2.0

	AGIO	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.1
Rev Chg Q	86.1%	7.5%
Rev Chg LTM	48.0%	6.8%
Rev Chg 3Y Avg	57.5%	5.7%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.5
CFO LTM ($ Bil)	-0.4
Net Inc LTM ($ Bil)	-0.4
Op Mgn LTM	-873.9%	18.6%
CFO/Rev LTM	-690.3%	20.6%
Net Inc Mgn	-764.0%	12.8%
VALUATION	VERY HIGH
P/S	35.6	3.2
P/CFO	-5.2	15.4
P/FCF	-5.0	19.8
P/E	-4.7	24.1
STABILITY	VERY GOOD
Debt/Equity	0.02	0.21
Cash/Assets	0.66	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Unique patients who completed PYRUKYND® prescription enrollment forms	248	6302025	Link
Patients on PYRUKYND® therapy	142	6302025	Link
Phase 3 RISE UP study enrollment	over 200 patients	10232024	Link

Upcoming
4/29/2026	Earnings Release	Rev: $13 Mil (E) EPS: $-1.81 (E)

Price Chart

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Agios Pharmaceuticals (AGIO) stock has gained about 20% since 12/31/2025 because of the following key factors:

1. U.S. Commercial Launch of AQVESME for Thalassemia and Strong PYRUKYND Sales Growth.

Agios Pharmaceuticals initiated the U.S. commercial launch of AQVESME (mitapivat) in late January 2026, following its FDA approval in December 2025 for the treatment of anemia in adults with alpha- or beta-thalassemia. This represents a new significant revenue stream for the company, as AQVESME is the only FDA-approved medicine for this indication. Additionally, U.S. sales of their existing drug, PYRUKYND, for pyruvate kinase deficiency in the fourth quarter of 2025 were $16.0 million, a 49% increase year-over-year.

2. Better-than-Expected Fourth Quarter 2025 Financial Results.

On February 12, 2026, Agios Pharmaceuticals reported its fourth-quarter and full-year 2025 financial results, surpassing analyst expectations. The company posted a narrower loss of $1.85 per share, beating estimates of -$1.99 by $0.14. Total revenue for the quarter reached $19.97 million, significantly exceeding the estimated $12.25 million by $7.72 million.

Show more

Stock Movement Drivers

Fundamental Drivers

The 21.0% change in AGIO stock from 12/31/2025 to 4/12/2026 was primarily driven by a 20.6% change in the company's Total Revenues ($ Mil).

(LTM values as of)	12312025	4122026	Change
Stock Price ($)	27.22	32.93	21.0%
Change Contribution By:
Total Revenues ($ Mil)	45	54	20.6%
P/S Multiple	35.3	35.6	0.7%
Shares Outstanding (Mil)	58	58	-0.4%
Cumulative Contribution			21.0%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/12/2026

	Return	Correlation
AGIO	20.9%
Market (SPY)	-5.4%	28.9%
Sector (XLV)	-4.8%	45.3%

Fundamental Drivers

The -18.0% change in AGIO stock from 9/30/2025 to 4/12/2026 was primarily driven by a -37.5% change in the company's P/S Multiple.

(LTM values as of)	9302025	4122026	Change
Stock Price ($)	40.14	32.93	-18.0%
Change Contribution By:
Total Revenues ($ Mil)	41	54	32.2%
P/S Multiple	56.9	35.6	-37.5%
Shares Outstanding (Mil)	58	58	-0.7%
Cumulative Contribution			-18.0%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/12/2026

	Return	Correlation
AGIO	-18.0%
Market (SPY)	-2.9%	9.3%
Sector (XLV)	6.3%	23.4%

Fundamental Drivers

The 12.4% change in AGIO stock from 3/31/2025 to 4/12/2026 was primarily driven by a 48.0% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312025	4122026	Change
Stock Price ($)	29.30	32.93	12.4%
Change Contribution By:
Total Revenues ($ Mil)	36	54	48.0%
P/S Multiple	45.8	35.6	-22.4%
Shares Outstanding (Mil)	57	58	-2.1%
Cumulative Contribution			12.4%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/12/2026

	Return	Correlation
AGIO	12.4%
Market (SPY)	16.3%	24.1%
Sector (XLV)	2.3%	30.4%

Fundamental Drivers

The 43.4% change in AGIO stock from 3/31/2023 to 4/12/2026 was primarily driven by a 279.4% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312023	4122026	Change
Stock Price ($)	22.97	32.93	43.4%
Change Contribution By:
Total Revenues ($ Mil)	14	54	279.4%
P/S Multiple	88.6	35.6	-59.9%
Shares Outstanding (Mil)	55	58	-5.8%
Cumulative Contribution			43.4%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/12/2026

	Return	Correlation
AGIO	43.3%
Market (SPY)	63.3%	27.7%
Sector (XLV)	19.1%	26.9%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
AGIO Return	-24%	-15%	-21%	48%	-17%	21%	-24%
Peers Return	-15%	13%	21%	-16%	46%	-6%	35%
S&P 500 Return	27%	-19%	24%	23%	16%	-0%	82%
Monthly Win Rates [3]
AGIO Win Rate	50%	42%	50%	58%	75%	75%
Peers Win Rate	42%	60%	50%	40%	62%	40%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
AGIO Max Drawdown	-32%	-48%	-29%	-4%	-32%	-3%
Peers Max Drawdown	-31%	-20%	-16%	-27%	-17%	-13%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, CRSP, BMRN, ALNY, IONS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)

How Low Can It Go

Unique Key	Event	AGIO	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-72.2%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	259.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	906 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-41.4%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	70.7%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	105 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-69.8%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	231.0%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	Not Fully Recovered days	120 days

Compare to VRTX, CRSP, BMRN, ALNY, IONS

In The Past

Agios Pharmaceuticals's stock fell -72.2% during the 2022 Inflation Shock from a high on 6/21/2021. A -72.2% loss requires a 259.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Agios Pharmaceuticals (AGIO)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AI Analysis | Feedback

Here are 1-2 brief analogies for Agios Pharmaceuticals (AGIO):

Like Alexion Pharmaceuticals, but dedicated to developing drugs for inherited metabolic blood disorders.
A BioMarin Pharmaceutical, but specializing in medicines for rare blood disorders linked to cellular metabolism.

AI Analysis | Feedback

PYRUKYND (mitapivat): An activator of pyruvate kinase (PK) enzymes for the treatment of hemolytic anemias.
AG-946: A product currently in Phase I clinical study for treating hemolytic anemias and other indications.

AI Analysis | Feedback

Agios Pharmaceuticals (AGIO), as a biopharmaceutical company developing and selling prescription medicines, primarily sells its products through major pharmaceutical wholesalers. These wholesalers then distribute the medicines to hospitals, pharmacies, and other healthcare providers.

The major customers of Agios Pharmaceuticals, Inc. are typically the three largest pharmaceutical wholesale distributors in the United States:

AmerisourceBergen Corporation (NYSE: ABC)
Cardinal Health, Inc. (NYSE: CAH)
McKesson Corporation (NYSE: MCK)

These companies act as intermediaries, purchasing the medicines directly from Agios and distributing them to the ultimate healthcare providers and patients.

AI Analysis | Feedback

null

AI Analysis | Feedback

Brian Goff

Chief Executive Officer

Brian Goff joined Agios as Chief Executive Officer and a member of its board of directors in August 2022. He has over 30 years of experience in the biopharmaceutical industry, with the last decade focused on rare diseases. Prior to Agios, he was Executive Vice President, Chief Commercial and Global Operations Officer of Alexion Pharmaceuticals until its acquisition by AstraZeneca in 2021. He also served as Chief Operating Officer and a board member of Neurovance, a venture-backed company that was acquired by Otsuka Pharmaceuticals in 2017. Before Neurovance, Mr. Goff was Executive Vice President and President of the hematology division at Baxalta until its acquisition by Shire Pharmaceuticals in 2016. His earlier career included roles at Baxter Healthcare Corporation, Novartis Pharmaceuticals, and nearly 14 years in the pharmaceutical division of Johnson & Johnson.

Cecilia Jones

Chief Financial Officer

Cecilia Jones was appointed Chief Financial Officer of Agios in September 2022. She brings over 20 years of financial experience in the biopharmaceutical industry, with a focus on rare diseases. Before joining Agios, Ms. Jones served as Chief Financial Officer at LogicBio Therapeutics, where she was responsible for the company's financial strategy, including evaluating financing alternatives, analyzing business development opportunities, and managing corporate financial planning, accounting, corporate communications, and investor relations. Prior to LogicBio, she spent over a decade at Biogen, holding various finance leadership roles, including Vice President of R&D, worldwide medical and business development finance, and Senior Director of Corporate Finance, where she led global long-range planning and financial assessments of business development and M&A opportunities. Earlier in her career, she was Director of International Finance at Genzyme.

Sarah Gheuens, M.D., Ph.D.

Chief Medical Officer, Head of Research & Development

Dr. Sarah Gheuens joined Agios in December 2019, becoming Chief Medical Officer in September 2021, and taking on the additional role of Head of Research & Development in August 2022. She has been instrumental in the completion of the pivotal Phase 3 program for pyruvate kinase deficiency, leading regulatory submissions to the FDA and EMA, and designing pivotal programs for thalassemia, sickle cell disease, and pediatric indications. Before Agios, Dr. Gheuens worked at Biogen in roles of increasing responsibility in safety, medical affairs, and clinical development, contributing to the approval of SPINRA®. Her prior experience includes working at Beth Israel Deaconess Medical Center (BIDMC) with HIV patients and conducting research on progressive multifocal leukoencephalopathy.

Jim Burns

Chief Legal Officer

Jim Burns serves as the Chief Legal Officer at Agios Pharmaceuticals. Previously, he held the position of Vice President, Commercial Healthcare Law & Chief Compliance Officer at the company.

Clive Patience, Ph.D.

Chief Technical Operations Officer

Dr. Clive Patience is the Chief Technical Operations Officer at Agios Pharmaceuticals. He previously held the role of Senior Vice President at Agios, which he joined in June 2017.

AI Analysis | Feedback

Key Business Risks for Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO) faces several significant risks inherent to the biopharmaceutical industry, particularly concerning regulatory hurdles, reliance on its lead product, and financial sustainability.

The most significant risk to Agios Pharmaceuticals is its **regulatory and clinical development risk**. The company's lead product, PYRUKYND (mitapivat), is undergoing regulatory review for additional indications, such as thalassemia, and has experienced delays, including an extended Prescription Drug User Fee Act (PDUFA) goal date and a missed target date by the FDA due to a request for a Risk Evaluation and Mitigation Strategy (REMS) to address safety concerns like hepatocellular injury (HCI). Any failure to secure approval or further delays for these expanded indications could significantly impact investor confidence and the company's market valuation. Additionally, there have been reports of deaths in PYRUKYND patients in the FDA's Adverse Events Reporting System (FAERS), raising safety concerns and potentially affecting market perception. Furthermore, pipeline candidates, such as AG-946, are in early-stage clinical development (Phase 1, advancing to Phase 2b for myelodysplastic syndromes), which inherently carry high failure rates and require successful trial outcomes and subsequent regulatory approvals for future growth. The Phase 3 RISE UP trial for PYRUKYND in sickle cell disease also yielded mixed results, meeting one primary endpoint but failing to significantly reduce annual pain crises, introducing uncertainty for that potential label expansion. General regulatory timing risks, including potential slowdowns from funding cuts or staff reductions at regulatory agencies, also pose a threat to clinical development timelines and revenues.

A second key risk is the company's **product concentration and heavy reliance on PYRUKYND**. PYRUKYND is considered the "centerpiece" of Agios's product pipeline and a "cornerstone" of its near-term growth strategy. The company's investment narrative heavily depends on PYRUKYND achieving commercial success across multiple rare blood disorders. This strong dependence on a single approved product means that any unforeseen challenges, such as unexpected adverse events, increased competition, or intellectual property disputes, could severely impact the company's financial performance and future growth prospects.

Finally, **ongoing operating losses and high research & development costs** present a significant financial risk. Despite showing consistent revenue growth, Agios has faced persistent operating losses and substantial costs associated with its clinical trials and general research and development efforts. The company exhibits negative EBITDA and EBIT margins, indicating challenges in cost management. While Agios maintains a strong financial position in terms of liquidity and low debt, continued operating losses and high expenses pose a challenge to achieving sustained profitability and long-term financial stability.


AI Analysis | Feedback
null
AI Analysis | Feedback
Agios Pharmaceuticals' main product, PYRUKYND (mitapivat), targets several distinct addressable markets within hemolytic anemias.


  For the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, the addressable market in the U.S. is estimated to be just less than 10,000 individuals.
  For adult patients with thalassemia in the U.S., Agios Pharmaceuticals targets a population of approximately 6,000 patients, with about 4,000 expected to be addressable at launch.


The company also states that its PYRUKYND franchise, which includes potential future indications like sickle cell disease and pediatric PK deficiency, is poised for multi-billion-dollar potential.

Agios Pharmaceuticals' other product, AG-946 (tebapivat), is in clinical development for indications such as lower-risk myelodysplastic syndromes (LR-MDS) and sickle cell disease. While these represent future market opportunities, specific addressable market sizes for AG-946 are not explicitly detailed in the provided information. Therefore, the addressable market size for AG-946 cannot be quantified at this time.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Agios Pharmaceuticals (AGIO)

  Continued Growth in Pyruvate Kinase (PK) Deficiency: Agios Pharmaceuticals expects sustained revenue growth from PYRUKYND (mitapivat) for the treatment of PK deficiency. The company projected U.S. PK deficiency revenues in the range of $45 million to $50 million for 2026. PYRUKYND generated $20 million in net revenue in Q4 2025, an 86% increase compared to Q4 2024, and $54 million for the full year 2025, reflecting robust year-on-year growth.
  U.S. Launch and Expansion of AQVESME (mitapivat) for Thalassemia: The recent FDA approval of AQVESME (mitapivat) for thalassemia in December 2025 is a significant new revenue driver. The U.S. launch is underway, with management focused on executing a high-impact launch and reporting strong early recognition and 44 prescriptions as of January 30, 2026. This expansion into thalassemia significantly broadens the addressable market for mitapivat.
  Potential Approval and Launch of Mitapivat in Sickle Cell Disease: Agios is actively pursuing the expansion of its PK activation franchise into sickle cell disease. The company completed enrollment in its Phase 3 RISE UP study for sickle cell disease in 2024 and is scheduled to meet with the FDA in Q1 2026 for a pre-sNDA meeting to determine the regulatory path forward, with a potential U.S. commercial launch anticipated in 2026.
  Advancement of PK Activation Franchise into Lower-Risk Myelodysplastic Syndromes (LR-MDS): Agios aims to expand its PK activation franchise into additional high-value indications, including lower-risk myelodysplastic syndromes. The company achieved clinical proof-of-concept in the Phase 2a portion of a study of investigational pyruvate kinase activator AG-946 for anemia in adults with LR-MDS, with plans to initiate the placebo-controlled Phase 2b portion of the study. Furthermore, a Phase 2 tebapivat trial in sickle cell disease is fully enrolled, with topline results expected in the second half of 2026.

AI Analysis | Feedback```html
Share Repurchases

Agios announced plans in April 2021 to repurchase 7.1 million shares from Bristol Myers Squibb Co. for approximately $344.5 million.
The company also indicated intentions to repurchase up to $1.2 billion in outstanding shares over the subsequent 12-18 months from April 2021.
As of December 31, 2025, the reported share buyback amount was $0.

Share Issuance

Agios Pharmaceuticals filed a Form S-8 on June 18, 2025, to register additional shares under its 2023 Stock Incentive Plan, enabling the continued issuance of equity-based compensation to employees, directors, and consultants.
Insiders have engaged in share transactions to cover tax withholding obligations related to restricted stock unit (RSU) vesting, as seen in December 2025 and March 2026.

Inbound Investments

In May 2025 (reported June 2024), Agios announced an agreement with Royalty Pharma to sell 15% of its royalties from Vorasidenib, resulting in a $905 million upfront payment contingent on FDA approval of Vorasidenib.
Agios sold its oncology portfolio, including Vorasidenib, to Servier in 2021, retaining rights to a $200 million payment upon FDA approval and 15% royalties on US net sales.
Agios Pharmaceuticals concluded fiscal year 2025 with approximately $1.2 billion in cash and marketable securities on its balance sheet.

Capital Expenditures

Agios's capital expenditures were $5.74 million in 2021, $3.92 million in 2022, -$0.33 million in 2023, $1.65 million in 2024, and $4.32 million in 2025.
In the fourth quarter of 2025, the company invested $1.1 million in capital expenditures.
For the last 12 months, capital expenditures were -$4.32 million.

```



	
		
			
				
					
					 Interactive Breakdown
null

null
				
			
		
	

	
		
			
				
				 Better Bets vs. Agios Pharmaceuticals (AGIO)
				
					By Industry
					By Sector
					All Other Sectors
					Sector Best Bets
				
				
					
				
					
						INDUSTRY: Biotechnology
					
			
					
						
							Higher Rev Chg 3Y Avg | Lower P/S 
							(Values for AGIO: 57.5% | 35.6x)
						
						
				
						
							BBIO (774.5% | 28.8x)
							BridgeBio Pharma
						
					
						
							AXSM (183.0% | 14.1x)
							Axsome Therapeutics
						
					
						
							ARWR (14468.6% | 8.2x)
							Arrowhead Pharmaceuticals
						
					
						
							RYTM (113.8% | 29.8x)
							Rhythm Pharmaceuticals
						
					
						
							MIRM (92.5% | 9.4x)
							Mirum Pharmaceuticals
						
					
					
						
							Higher Rev Chg LTM 
							(Value for AGIO: 48.0%)
						
						
				
						
							MDGL (432.1%)
							Madrigal Pharmaceuticals
						
					
						
							BBIO (126.3%)
							BridgeBio Pharma
						
					
						
							INSM (66.7%)
							Insmed
						
					
						
							AXSM (65.5%)
							Axsome Therapeutics
						
					
						
							ALNY (65.2%)
							Alnylam Pharmaceuticals
						
					
					
						
							Higher Rev Chg 3Y Avg 
							(Value for AGIO: 57.5%)
						
						
				
						
							ARWR (14468.6%)
							Arrowhead Pharmaceuticals
						
					
						
							IBRX (1032.7%)
							ImmunityBio
						
					
						
							BBIO (774.5%)
							BridgeBio Pharma
						
					
						
							AXSM (183.0%)
							Axsome Therapeutics
						
					
						
							CYTK (143.3%)
							Cytokinetics
						
					
					
						
							Higher Op Mgn LTM 
							(Value for AGIO: -873.9%)
						
						
				
						
							GILD (39.7%)
							Gilead Sciences
						
					
						
							VRTX (37.9%)
							Vertex Pharmaceuticals
						
					
						
							ABBV (32.8%)
							AbbVie
						
					
						
							REGN (25.8%)
							Regeneron Pharmaceuticals
						
					
						
							AMGN (24.7%)
							Amgen
						
					
					
						
							Higher CFO/Rev LTM 
							(Value for AGIO: -690.3%)
						
						
				
						
							REGN (34.7%)
							Regeneron Pharmaceuticals
						
					
						
							GILD (34.0%)
							Gilead Sciences
						
					
						
							ABBV (31.1%)
							AbbVie
						
					
						
							VRTX (30.3%)
							Vertex Pharmaceuticals
						
					
						
							AMGN (27.1%)
							Amgen
						
					
					
						
							Higher FCF/Rev LTM 
							(Value for AGIO: -716.8%)
						
						
				
						
							GILD (32.1%)
							Gilead Sciences
						
					
						
							ABBV (29.1%)
							AbbVie
						
					
						
							VRTX (26.6%)
							Vertex Pharmaceuticals
						
					
						
							REGN (26.3%)
							Regeneron Pharmaceuticals
						
					
						
							AMGN (22.0%)
							Amgen
						
					
					
						
							Higher Total Yield 
							(Value for AGIO: -21.5%)
						
						
				
						
							GILD (7.3%)
							Gilead Sciences
						
					
						
							AMGN (6.8%)
							Amgen
						
					
						
							REGN (6.3%)
							Regeneron Pharmaceuticals
						
					
						
							ABBV (4.3%)
							AbbVie
						
					
						
							VRTX (3.6%)
							Vertex Pharmaceuticals
						
					
					
				
					
						SECTOR: Health Care
					
			
					
						
							Higher Rev Chg 3Y Avg | Lower P/S 
							(Values for AGIO: 57.5% | 35.6x)
						
						
				
						
							BBIO (774.5% | 28.8x)
							BridgeBio Pharma
						
					
						
							AXSM (183.0% | 14.1x)
							Axsome Therapeutics
						
					
						
							ARWR (14468.6% | 8.2x)
							Arrowhead Pharmaceuticals
						
					
						
							TEM (58.8% | 6.0x)
							Tempus AI
						
					
						
							RYTM (113.8% | 29.8x)
							Rhythm Pharmaceuticals
						
					
					
						
							Higher Rev Chg LTM 
							(Value for AGIO: 48.0%)
						
						
				
						
							MDGL (432.1%)
							Madrigal Pharmaceuticals
						
					
						
							BBIO (126.3%)
							BridgeBio Pharma
						
					
						
							INSM (66.7%)
							Insmed
						
					
						
							AXSM (65.5%)
							Axsome Therapeutics
						
					
						
							ALNY (65.2%)
							Alnylam Pharmaceuticals
						
					
					
						
							Higher Rev Chg 3Y Avg 
							(Value for AGIO: 57.5%)
						
						
				
						
							ARWR (14468.6%)
							Arrowhead Pharmaceuticals
						
					
						
							BBIO (774.5%)
							BridgeBio Pharma
						
					
						
							AXSM (183.0%)
							Axsome Therapeutics
						
					
						
							CYTK (143.3%)
							Cytokinetics
						
					
						
							TEM (58.8%)
							Tempus AI
						
					
					
						
							Higher Op Mgn LTM 
							(Value for AGIO: -873.9%)
						
						
				
						
							LLY (45.6%)
							Eli Lilly
						
					
						
							MRK (34.0%)
							Merck
						
					
						
							ABBV (32.8%)
							AbbVie
						
					
						
							JNJ (27.2%)
							Johnson & Johnson
						
					
						
							UNH (4.2%)
							UnitedHealth
						
					
					
						
							Higher CFO/Rev LTM 
							(Value for AGIO: -690.3%)
						
						
				
						
							ABBV (31.1%)
							AbbVie
						
					
						
							JNJ (26.0%)
							Johnson & Johnson
						
					
						
							LLY (25.8%)
							Eli Lilly
						
					
						
							MRK (25.3%)
							Merck
						
					
						
							UNH (4.4%)
							UnitedHealth
						
					
					
						
							Higher FCF/Rev LTM 
							(Value for AGIO: -716.8%)
						
						
				
						
							ABBV (29.1%)
							AbbVie
						
					
						
							JNJ (20.5%)
							Johnson & Johnson
						
					
						
							MRK (19.0%)
							Merck
						
					
						
							LLY (9.2%)
							Eli Lilly
						
					
						
							UNH (3.6%)
							UnitedHealth
						
					
					
						
							Higher Total Yield 
							(Value for AGIO: -21.5%)
						
						
				
						
							MRK (8.8%)
							Merck
						
					
						
							UNH (7.2%)
							UnitedHealth
						
					
						
							JNJ (6.8%)
							Johnson & Johnson
						
					
						
							ABBV (4.3%)
							AbbVie
						
					
						
							LLY (3.1%)
							Eli Lilly
						
					
					
				
					
						All Other Sectors
					
			
					
						
							Higher Rev Chg 3Y Avg | Lower P/S 
							(Values for AGIO: 57.5% | 35.6x)
						
						
				
						
							NVDA (101.8% | 21.2x)
							NVIDIA
						
					
						
							KKR (65.2% | 4.2x)
							KKR
						
					
						
							NU (63129.4% | 6.8x)
							Nu
						
					
						
							APO (66.8% | 1.9x)
							Apollo Global Management
						
					
						
							SLF (322.2% | 0.9x)
							Sun Life Financial
						
					
					
						
							Higher Rev Chg LTM 
							(Value for AGIO: 48.0%)
						
						
				
						
							MU (85.5%)
							Micron Technology
						
					
						
							NVDA (65.5%)
							NVIDIA
						
					
						
							APP (61.1%)
							AppLovin
						
					
						
							PLTR (56.2%)
							Palantir Technologies
						
					
						
							APH (51.7%)
							Amphenol
						
					
					
						
							Higher Rev Chg 3Y Avg 
							(Value for AGIO: 57.5%)
						
						
				
						
							NU (63129.4%)
							Nu
						
					
						
							SLF (322.2%)
							Sun Life Financial
						
					
						
							NVDA (101.8%)
							NVIDIA
						
					
						
							APO (66.8%)
							Apollo Global Management
						
					
						
							KKR (65.2%)
							KKR
						
					
					
						
							Higher Op Mgn LTM 
							(Value for AGIO: -873.9%)
						
						
				
						
							NVDA (60.4%)
							NVIDIA
						
					
						
							MSFT (46.7%)
							Microsoft
						
					
						
							AAPL (32.4%)
							Apple
						
					
						
							GOOGL (32.0%)
							Alphabet
						
					
						
							AMZN (11.2%)
							Amazon.com
						
					
					
						
							Higher CFO/Rev LTM 
							(Value for AGIO: -690.3%)
						
						
				
						
							MSFT (52.5%)
							Microsoft
						
					
						
							NVDA (47.6%)
							NVIDIA
						
					
						
							GOOGL (40.9%)
							Alphabet
						
					
						
							AAPL (31.1%)
							Apple
						
					
						
							AMZN (19.5%)
							Amazon.com
						
					
					
						
							Higher FCF/Rev LTM 
							(Value for AGIO: -716.8%)
						
						
				
						
							NVDA (44.8%)
							NVIDIA
						
					
						
							AAPL (28.3%)
							Apple
						
					
						
							MSFT (25.3%)
							Microsoft
						
					
						
							GOOGL (18.2%)
							Alphabet
						
					
						
							AMZN (1.1%)
							Amazon.com
						
					
					
						
							Higher Total Yield 
							(Value for AGIO: -21.5%)
						
						
				
						
							MSFT (5.2%)
							Microsoft
						
					
						
							GOOGL (3.7%)
							Alphabet
						
					
						
							AAPL (3.5%)
							Apple
						
					
						
							AMZN (3.0%)
							Amazon.com
						
					
						
							NVDA (2.6%)
							NVIDIA
						
					
					
				
					
						Best Bets in Health Care
					
			What You Pay
					
						
							P/EBIT 
							(Value for AGIO: -4.1x)
						
						
				
						
							RPRX (12.6x)
							Royalty Pharma
						
					
						
							DOCS (16.5x)
							Doximity
						
					
						
							VEEV (27.0x)
							Veeva Systems
						
					
						
							HALO (16.5x)
							Halozyme Therapeutics
						
					
						
							UTHR (14.3x)
							United Therapeutics
						
					
						
							CPRX (11.9x)
							Catalyst Pharmaceuticals
						
					
						
							BMY (10.6x)
							Bristol-Myers Squibb
						
					
						
							RMD (18.1x)
							ResMed
						
					
						
							AMGN (16.1x)
							Amgen
						
					
						
							PBH (8.8x)
							Prestige Consumer Healthcare
						
					
					
						
							P/E 
							(Value for AGIO: -4.7x)
						
						
				
						
							RPRX (26.6x)
							Royalty Pharma
						
					
						
							DOCS (16.5x)
							Doximity
						
					
						
							VEEV (27.3x)
							Veeva Systems
						
					
						
							HALO (25.2x)
							Halozyme Therapeutics
						
					
						
							UTHR (18.6x)
							United Therapeutics
						
					
						
							CPRX (14.3x)
							Catalyst Pharmaceuticals
						
					
						
							BMY (16.9x)
							Bristol-Myers Squibb
						
					
						
							RMD (22.5x)
							ResMed
						
					
						
							AMGN (24.5x)
							Amgen
						
					
						
							PBH (14.5x)
							Prestige Consumer Healthcare
						
					
What You Get
					
						
							Rev Chg 3Y Avg 
							(Value for AGIO: 57.5%)
						
						
				
						
							RPRX (2.1%)
							Royalty Pharma
						
					
						
							DOCS (16.7%)
							Doximity
						
					
						
							VEEV (14.1%)
							Veeva Systems
						
					
						
							HALO (28.5%)
							Halozyme Therapeutics
						
					
						
							UTHR (18.1%)
							United Therapeutics
						
					
						
							CPRX (43.1%)
							Catalyst Pharmaceuticals
						
					
						
							BMY (1.5%)
							Bristol-Myers Squibb
						
					
						
							RMD (12.9%)
							ResMed
						
					
						
							AMGN (11.9%)
							Amgen
						
					
						
							PBH (-0.1%)
							Prestige Consumer Healthcare
						
					
					
						
							Rev Chg LTM 
							(Value for AGIO: 48.0%)
						
						
				
						
							RPRX (5.1%)
							Royalty Pharma
						
					
						
							DOCS (15.9%)
							Doximity
						
					
						
							VEEV (16.3%)
							Veeva Systems
						
					
						
							HALO (37.6%)
							Halozyme Therapeutics
						
					
						
							UTHR (10.6%)
							United Therapeutics
						
					
						
							CPRX (19.8%)
							Catalyst Pharmaceuticals
						
					
						
							BMY (-0.2%)
							Bristol-Myers Squibb
						
					
						
							RMD (9.6%)
							ResMed
						
					
						
							AMGN (10.0%)
							Amgen
						
					
						
							PBH (-1.3%)
							Prestige Consumer Healthcare
						
					
					
						
							Rev Chg Q 
							(Value for AGIO: 86.1%)
						
						
				
						
							RPRX (4.8%)
							Royalty Pharma
						
					
						
							DOCS (9.8%)
							Doximity
						
					
						
							VEEV (16.0%)
							Veeva Systems
						
					
						
							HALO (51.6%)
							Halozyme Therapeutics
						
					
						
							UTHR (7.4%)
							United Therapeutics
						
					
						
							CPRX (7.6%)
							Catalyst Pharmaceuticals
						
					
						
							BMY (1.3%)
							Bristol-Myers Squibb
						
					
						
							RMD (11.0%)
							ResMed
						
					
						
							AMGN (8.6%)
							Amgen
						
					
						
							PBH (-2.4%)
							Prestige Consumer Healthcare
						
					
					
						
							FCF/Rev 3Y Avg 
							(Value for AGIO: -987.4%)
						
						
				
						
							RPRX (118.0%)
							Royalty Pharma
						
					
						
							DOCS (41.6%)
							Doximity
						
					
						
							VEEV (40.8%)
							Veeva Systems
						
					
						
							HALO (38.8%)
							Halozyme Therapeutics
						
					
						
							UTHR (34.1%)
							United Therapeutics
						
					
						
							CPRX (33.2%)
							Catalyst Pharmaceuticals
						
					
						
							BMY (27.9%)
							Bristol-Myers Squibb
						
					
						
							RMD (27.3%)
							ResMed
						
					
						
							AMGN (26.4%)
							Amgen
						
					
						
							PBH (22.3%)
							Prestige Consumer Healthcare
						
					
			
				[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52
			
		
				
			
		
	

	
		
			
				
				 Latest Trefis Analyses
				 Title Date
0 DASHBOARDS  
1 Agios Stock (+19%): AQVESME Thalassemia Approval Ignites Re-Rate 12/25/2025
2 Agios Pharmaceuticals Earnings Notes 12/16/2025
3 Would You Still Hold Agios Pharmaceuticals Stock If It Fell Another 30%? 10/17/2025
4 Does Agios Pharmaceuticals Stock Lead the Pack? 08/13/2025
5 Why Agios Pharmaceuticals Stock Moved: AGIO Stock Has Lost 26% Since 2021 Fiscal End, Primarily Due To Unfavorable Change In Price To Sales Multiple (P/S) 08/08/2025
6 AGIO Dip Buy Analysis 07/10/2025
7 Agios Pharmaceuticals Stock Falls 10% In A Single Week, Now Is Not The Time To Buy The Stock 05/16/2025
8 Agios Pharmaceuticals (AGIO) Valuation Ratios Comparison 05/15/2025
9 Agios Pharmaceuticals Total Shareholder Return (TSR): 47.6% in 2024 and 0.0% 3-yr compounded annual returns (below peer average) 03/07/2025
10 Agios Pharmaceuticals (AGIO) Operating Cash Flow Comparison 02/17/2025
11 ARTICLES  
12 Market Movers | Winners: WSHP, SGBX, SEMR | Losers: IVP, AGIO, TPST 11/20/2025
 Title
0 DASHBOARDS
1 Agios Stock (+19%): AQVESME Thalassemia Approval Ignites Re-Rate
2 Agios Pharmaceuticals Earnings Notes
3 Would You Still Hold Agios Pharmaceuticals Stock If It Fell Another 30%?
4 Does Agios Pharmaceuticals Stock Lead the Pack?
5 Why Agios Pharmaceuticals Stock Moved: AGIO Stock Has Lost 26% Since 2021 Fiscal End, Primarily Due To Unfavorable Change In Price To Sales Multiple (P/S)
6 AGIO Dip Buy Analysis
7 Agios Pharmaceuticals Stock Falls 10% In A Single Week, Now Is Not The Time To Buy The Stock
8 Agios Pharmaceuticals (AGIO) Valuation Ratios Comparison
9 Agios Pharmaceuticals Total Shareholder Return (TSR): 47.6% in 2024 and 0.0% 3-yr compounded annual returns (below peer average)
10 Agios Pharmaceuticals (AGIO) Operating Cash Flow Comparison
11 ARTICLES
12 Market Movers | Winners: WSHP, SGBX, SEMR | Losers: IVP, AGIO, TPST
			
		
	

	
		
			
				
				 Trade Ideas
Select ideas related to AGIO.
Unique Key Date Ticker Company Category Trade Strategy 6M Fwd Rtn 12M Fwd Rtn 12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG 03312026 PGNY Progyny Dip Buy DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap 0.0% 0.0% 0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG 03272026 CNC Centene Dip Buy DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap 2.3% 2.3% -0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG 03272026 OSCR Oscar Health Dip Buy DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap 3.0% 3.0% -2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper 03202026 WAT Waters Monopoly MY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple -0.4% -0.4% -3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10% 03202026 GILD Gilead Sciences Quality Q | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run 1.6% 1.6% -2.2%
			
		
	

	
		
			
				
				 Recent Active Movers
				
					1D
					1W
					1M
				
				
					Top Gainers
Ticker Company Mkt Cap (B) 1D Rtn YTD Rtn
OGN Organon 2.3 27.8% 23.5%
LWLG Lightwave Logic 1.4 25.6% 227.2%
POET POET Technologies 0.6 15.8% 11.2%
ALAB Astera Labs 25.3 15.1% -10.4%
MANE Veradermics 1.4 14.7% 82.3%
TTMI TTM Technologies 12.6 13.0% 76.1%
AAOI Applied Optoelectronics 10.6 13.0% 332.0%
FBYD Falcons Beyond Global 0.5 12.6% -18.9%
TE T1 Energy 0.8 12.2% -29.8%
CRWV CoreWeave 51.7 10.9% 42.4%
Top Losers
Ticker Company Mkt Cap (B) 1D Rtn YTD Rtn
FSLY Fastly 3.5 -21.7% 126.6%
REPL Replimune 0.4 -19.5% -51.0%
AKAM Akamai Technologies 13.2 -16.7% 4.7%
FICO Fair Isaac 21.9 -14.0% -45.4%
SEZL Sezzle 2.0 -13.6% -5.9%
NET Cloudflare 58.6 -13.5% -15.3%
DOCN DigitalOcean 6.9 -13.3% 57.1%
SMPL Simply Good Foods 1.0 -11.5% -48.0%
EVMN Evommune 0.8 -11.0% 49.0%
GH Guardant Health 10.1 -9.8% -23.0%
					Top Gainers
Ticker Company Mkt Cap (B) 1W Rtn YTD Rtn
AEHR Aehr Test Systems 2.1 58.9% 248.8%
CAR Avis Budget 10.6 57.5% 133.7%
AAOI Applied Optoelectronics 10.6 44.9% 332.0%
OGN Organon 2.3 38.8% 23.5%
LWLG Lightwave Logic 1.4 38.4% 227.2%
HUT Hut 8 7.2 37.4% 43.9%
SLNO Soleno Therapeutics 2.8 33.3% 13.7%
STAA Staar Surgical 1.3 30.8% 14.5%
RIOT Riot Platforms 5.8 29.1% 31.0%
CIFR Cipher Digital 6.6 28.9% 12.0%
Top Losers
Ticker Company Mkt Cap (B) 1W Rtn YTD Rtn
REPL Replimune 0.4 -43.4% -51.0%
FSLY Fastly 3.5 -31.1% 126.6%
SMPL Simply Good Foods 1.0 -26.3% -48.0%
AKAM Akamai Technologies 13.2 -22.6% 4.7%
GWRE Guidewire Software 10.0 -21.8% -41.3%
OKTA Okta 11.2 -21.5% -27.2%
HUBS HubSpot 10.1 -21.4% -52.1%
NET Cloudflare 58.6 -21.1% -15.3%
VRDN Viridian Therapeutics 1.4 -20.6% -52.0%
SNOW Snowflake 41.5 -20.2% -44.8%
					Top Gainers
Ticker Company Mkt Cap (B) 1M Rtn YTD Rtn
XLO Xilio Therapeutics 0.6 1475.9% -5.1%
CAR Avis Budget 10.6 196.4% 133.7%
SATL Satellogic 1.0 135.7% 292.0%
LWLG Lightwave Logic 1.4 111.2% 227.2%
APLS Apellis Pharmaceuticals 5.2 110.5% 62.4%
FBYD Falcons Beyond Global 0.5 92.1% -18.9%
FLY Firefly Aerospace 6.0 82.2% 67.8%
KOD Kodiak Sciences 2.3 75.7% 54.2%
KODK Eastman Kodak 1.2 74.0% 42.9%
ORKA Oruka Therapeutics 3.2 73.1% 96.6%
Top Losers
Ticker Company Mkt Cap (B) 1M Rtn YTD Rtn
WVE WAVE Life Sciences 1.3 -49.0% -57.8%
VRDN Viridian Therapeutics 1.4 -47.8% -52.0%
MAZE Maze Therapeutics 1.2 -47.1% -35.6%
BUR Burford Capital 1.0 -47.0% -51.1%
FRMI Fermi 2.9 -43.9% -39.1%
TE T1 Energy 0.8 -42.4% -29.8%
REPL Replimune 0.4 -39.7% -51.0%
ADMA ADMA Biologics 2.3 -38.1% -46.8%
FIG Figma 9.3 -34.8% -51.4%
BOBS Bobs Discount Furniture 1.4 -34.7% -34.8%
				
			
		
	

	
		 More From Trefis
		
			
				Research & Analysis
				
					Latest Ideas
					Dip Buying Opportunities
					Earnings Reaction Data
				
			
		
		
			
				Invest in Strategies
				
					Invest in Trefis Strategies
					Advisor Strategies & Resources
				
			
		
		
			
				Wealth Management
				
					Help Me Invest
					Rules-Based Wealth Management
				
			
		
	

	
		
			
				 Peer Comparisons
Peers to compare with: 
				
				Financials
 AGIO VRTX CRSP BMRN ALNY IONS Median
Name Agios Ph. Vertex P. CRISPR T. BioMarin. Alnylam . Ionis Ph.  
Mkt Price 32.93 436.68 51.28 54.52 322.11 75.26 64.89
Mkt Cap 1.9 110.7 4.9 10.5 42.6 12.2 11.4
Rev LTM 54 12,001 0 3,221 3,714 944 2,082
Op Inc LTM -472 4,554 -665 409 502 -382 14
FCF LTM -387 3,194 -371 717 465 -326 70
FCF 3Y Avg -364 1,832 -263 415 155 -405 -54
CFO LTM -373 3,631 -345 828 524 -269 128
CFO 3Y Avg -353 2,225 -249 520 207 -359 -21
				Growth & Margins
 AGIO VRTX CRSP BMRN ALNY IONS Median
Name Agios Ph. Vertex P. CRISPR T. BioMarin. Alnylam . Ionis Ph.  
Rev Chg LTM 48.0% 8.9% -100.0% 12.9% 65.2% 33.8% 23.4%
Rev Chg 3Y Avg 57.5% 10.4% 28,190.6% 15.4% 54.8% 19.2% 37.0%
Rev Chg Q 86.1% 9.5% -100.0% 17.0% 84.9% -10.3% 13.3%
QoQ Delta Rev Chg LTM 20.6% 2.4% -100.0% 4.1% 15.7% -2.4% 3.2%
Op Mgn LTM -873.9% 37.9% - 12.7% 13.5% -40.5% 12.7%
Op Mgn 3Y Avg -1,166.6% 24.7% - 12.9% -3.3% -50.9% -3.3%
QoQ Delta Op Mgn LTM 187.9% 38.7% - -7.2% 5.3% -11.7% 5.3%
CFO/Rev LTM -690.3% 30.3% - 25.7% 14.1% -28.5% 14.1%
CFO/Rev 3Y Avg -954.1% 20.5% - 17.5% 6.5% -46.2% 6.5%
FCF/Rev LTM -716.8% 26.6% - 22.3% 12.5% -34.5% 12.5%
FCF/Rev 3Y Avg -987.4% 17.0% - 13.7% 4.3% -51.9% 4.3%
				Valuation
 AGIO VRTX CRSP BMRN ALNY IONS Median
Name Agios Ph. Vertex P. CRISPR T. BioMarin. Alnylam . Ionis Ph.  
Mkt Cap 1.9 110.7 4.9 10.5 42.6 12.2 11.4
P/S 35.6 9.2 - 3.3 11.5 13.0 11.5
P/EBIT -4.1 23.8 -7.4 21.2 74.0 -41.3 8.6
P/E -4.7 28.0 -8.4 30.0 135.8 -32.0 11.7
P/CFO -5.2 30.5 -14.2 12.7 81.3 -45.5 3.8
Total Yield -21.5% 3.6% -11.9% 3.3% 0.7% -3.1% -1.2%
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FCF Yield 3Y Avg -23.5% 1.7% -5.7% 3.5% 0.3% -5.7% -2.7%
D/E 0.0 0.0 0.0 0.1 0.0 0.2 0.0
Net D/E -0.4 -0.0 -0.4 -0.1 -0.0 -0.1 -0.1
				Returns
 AGIO VRTX CRSP BMRN ALNY IONS Median
Name Agios Ph. Vertex P. CRISPR T. BioMarin. Alnylam . Ionis Ph.  
1M Rtn 18.2% -7.0% 5.2% -6.8% 2.8% 5.7% 4.0%
3M Rtn 15.9% -5.9% -4.8% -7.5% -19.1% -6.3% -6.1%
6M Rtn -18.9% 7.1% -29.8% 4.2% -30.0% 7.6% -7.4%
12M Rtn 23.3% -9.8% 30.5% -4.0% 35.5% 169.7% 26.9%
3Y Rtn 46.3% 31.0% 1.4% -44.6% 55.4% 100.4% 38.6%
1M Excs Rtn 16.7% -11.9% 2.1% -10.2% -0.1% 0.0% -0.0%
3M Excs Rtn 18.5% -5.5% -7.6% -8.1% -17.8% -6.2% -6.9%
6M Excs Rtn -23.6% 2.8% -34.1% -1.2% -29.5% 6.6% -12.4%
12M Excs Rtn -2.6% -44.4% 27.1% -39.3% 6.8% 158.2% 2.1%
3Y Excs Rtn -13.8% -27.4% -49.0% -109.1% -7.3% 46.6% -20.6%
				Comparison Analyses
 Title
0 Does Agios Pharmaceuticals Stock Lead the Pack?
			
		
	

	
		
			
				
				 FDIC Bank Data
				Capital & Deposits
Assets
Loans
				
					Bank Capital
nullBank Deposits
null
					Bank Assets
null
					Bank Loans
null
				
			
		
	

	
		
			
				
				 FDA Approved Drugs Data
				Expand for More Post-Approval Fwd Returns
FDA
App # Brand
Name Generic
Name Dosage
Form FDA
Approval 3M
Rtn 6M
Rtn 1Y
Rtn 2Y
Rtn Total
Rtn
NDA216196   PYRUKYND mitapivat sulfate tablet 2172022 -30.0% -11.2% -6.0% -10.0% 11.7%
				Collapse to Preview Post-Approval Fwd Returns
FDA
App # Brand
Name Generic
Name Dosage
Form FDA
Approval 3M
Rtn 6M
Rtn 1Y
Rtn 2Y
Rtn Total
Rtn
NDA216196   PYRUKYND mitapivat sulfate tablet 2172022 -30.0% -11.2% -6.0% -10.0% 11.7%
			
		
	

	
		
			
				
				 Financials
				Annual
Quarterly
				$ Mil | FY: 12/31 LTM 2025 2024 2023 2022 2021 2020
Period End 12/31/2025 12/31/2025 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Filing Date 2/12/2026 2/12/2026 2/13/2025 2/15/2024 2/23/2023 2/24/2022 2/25/2021

Key Financials              
Total Revenue 54 54 36 27 14 0 0
EBITDA -467 -467 -420 -385 -380 -369 -326
Operating Income -472 -472 -426 -391 -389 -378 -336
Net Income -413 -413 674 -352 -232 1,605 -327
EPS -7.11 -7.12 11.86 -6.33 -4.23 26.55 -4.74

Growth Rates              
Total Revenue Growth 48.0% 48.0% 36.1% 88.4% ∞% - -
EBITDA Growth -11.2% -11.2% -9.2% -1.2% -3.1% -13.2% -5.8%
Operating Income Growth -10.9% -10.9% -8.7% -0.6% -2.8% -12.7% -6.2%
Net Income Growth -161.3% -161.3% 291.4% -51.9% -114.4% 590.2% 20.4%

Margins              
EBITDA Margin -864.3% -864.3% -1151.0% -1434.8% -2671.9% - -
Operating Income Margin -873.9% -873.9% -1166.5% -1459.5% -2732.1% - -
Net Income Margin -764.0% -764.0% 1845.9% -1312.6% -1627.8% - -

Cash & Debt              
Total Cash 854 854 894 777 783 1,020 573
Total Debt 40 40 57 72 86 97 105
Net Debt / (Cash) -814 -814 -837 -705 -697 -923 -468

Cash Flows              
Net Cash from Operations -373 -373 -390 -296 -309 -407 -291
Free Cash from Operations -387 -387 -392 -315 -314 -413 -305

Returns to Shareholders              
Dividends 0 -0 -0 -0 -0 -0 -0
Share Repurchases -0 -0 -0 -0 -0 802 -0
$ Mil | FY: 12/31 2025Q4 2025Q3 2025Q2 2025Q1 2024Q4 2024Q3 2024Q2 2024Q1 2023Q4 2023Q3 2023Q2 2023Q1
Period End 12/31/2025 9/30/2025 6/30/2025 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Filing Date 2/12/2026 10/30/2025 7/31/2025 5/1/2025 2/13/2025 10/31/2024 8/1/2024 5/2/2024 2/15/2024 11/2/2023 8/3/2023 5/4/2023

Key Financials Quarterly                        
Total Revenue 20 13 12 9 11 9 9 8 7 7 7 6
Ebitda -120 -115 -126 -105 -124 -101 -104 -91 -105 -99 -92 -89
Operating Income -122 -117 -127 -107 -125 -103 -106 -92 -106 -101 -94 -91
Net Income -108 -103 -112 -89 -97 948 -96 -82 -96 -91 -84 -81
EPS -1.85 -1.78 -1.93 -1.55 -1.72 16.65 -1.69 -1.45 -1.72 -1.64 -1.51 -1.47

Key Financials TTM                        
Total Revenue TTM 54 45 41 37 36 33 31 29 27 24 20 19
Ebitda TTM -467 -470 -456 -435 -420 -401 -399 -387 -385 -377 -367 -371
Operating Income TTM -472 -476 -462 -440 -426 -407 -405 -393 -391 -384 -375 -379
Net Income TTM -413 -401 650 666 674 674 -365 -353 -352 -220 -210 -218

Growth Rates Quarterly                        
Total Revenue Growth 86.1% 43.7% 44.6% 6.6% 51.1% 21.2% 28.4% 46.0% 64.8% 110.4% 20.2% 574.2%
EBITDA Growth 2.7% -13.8% -20.7% -16.1% -17.9% -2.2% -13.4% -2.1% -7.7% -11.4% 3.6% 10.0%
Operating Income Growth 2.8% -13.7% -20.1% -15.8% -17.7% -1.9% -12.9% -1.6% -7.2% -10.8% 4.0% 10.4%
Net Income Growth -11.9% -110.9% -16.5% -9.5% -0.6% 1138.0% -14.7% -0.7% -362.7% -11.7% 8.7% 14.5%

Margins Quarterly                        
EBITDA Margin -602.6% -896.7% -1010.0% -1207.3% -1152.6% -1131.9% -1209.8% -1107.9% -1476.5% -1341.7% -1369.1% -1583.6%
Operating Income Margin -608.9% -907.4% -1020.1% -1222.0% -1165.3% -1146.9% -1228.3% -1124.3% -1496.2% -1363.7% -1396.0% -1615.5%
Net Income Margin -541.1% -803.1% -899.4% -1023.3% -899.6% 10574.7% -1115.7% -995.8% -1350.7% -1234.3% -1248.6% -1444.4%

Cash & Debt                        
Total Cash 854 953 939 893 894 1,005 570 598 777 647 703 739
Total Debt 40 45 49 53 57 61 65 68 72 75 79 82
Net Debt / (Cash) -814 -908 -890 -840 -837 -944 -505 -530 -705 -572 -624 -657

Cash Flows Quarterly                        
FCF from Operations -96 -88 -77 -111 -133 -84 -73 -100 -72 -62 -67 -95

Cash Flows TTM                        
FCF from Operations TTM -373 -410 -406 -401 -390 -329 -307 -301 -296 -290 -299 -307

Returns to Shareholders Quarterly                        
Dividends 0 0 0 0 0 0 0 0 0 0 0 0
Share Repurchases -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0

Return on Invested Capital (ROIC) Quarterly                        
ROIC -348.8% -1720.9% -1873.6% -689.9% -903.9% - -119.9% -116.6% -336.7% -168.8% -216.0% -281.5%

Return on Invested Capital (ROIC) TTM                        
ROIC TTM -341.8% -1750.7% -1701.5% -712.2% -840.2% - -114.7% -124.4% -310.1% -160.8% -215.9% -294.0%
			
		
	

	
		
			
				
				 Segment Financials
Revenue by Segment
$ Mil 2025 2024 2023 2022 2021
Product revenue, net 27 12     60
Milestone revenue 0 2      
Collaboration revenue – other         11
Collaboration revenue – related party         39
Royalty revenue – related party         8
Total 27 14     118


Assets by Segment
$ Mil 2025 2024 2023 2022 2021
Single segment     1,438 853  
Total     1,438 853  



			
		
	

	
		
			
				
				 Price Behavior
				Behavior Stats
Betas Matrix
Behavior vs Other Asset Classes
				
					Price Behavior
Market Price $32.92  
Market Cap ($ Bil) 1.9  
First Trading Date 07/24/2013  
Distance from 52W High -27.6%  
    50 Days 200 Days
DMA Price $29.29 $33.76
DMA Trend indeterminate up
Distance from DMA 12.4% -2.5%
  3M 1YR
Volatility 44.2% 70.1%
Downside Capture 0.02 0.32
Upside Capture 114.99 70.65
Correlation (SPY) 21.9% 17.9%
					
AGIO Betas & Captures as of 3/31/2026


  1M 2M 3M 6M 1Y 3Y
Beta 1.35 0.79 0.77 0.66 0.88 1.06
Up Beta 4.69 1.16 1.59 2.48 0.96 0.91
Down Beta 0.09 0.75 0.49 0.08 0.81 0.78
Up Capture 185% 115% 112% -13% 56% 171%
Bmk +ve Days 7 16 27 65 139 424
Stock +ve Days 10 21 30 63 131 373
Down Capture 86% 23% 37% 60% 87% 107%
Bmk -ve Days 12 23 33 58 110 323
Stock -ve Days 12 21 33 63 120 374


[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
					
						
							1Y
							5Y
							10Y
						
						
							Based On 1-Year Data
 Annualized
Return Annualized
Volatility Sharpe
Ratio Correlation
with AGIO
AGIO 34.9% 70.4% 0.82 -
Sector ETF (XLV) 12.3% 16.8% 0.52 27.4%
Equity (SPY) 31.2% 17.3% 1.47 21.3%
Gold (GLD) 60.1% 27.8% 1.69 4.0%
Commodities (DBC) 29.8% 16.6% 1.58 7.6%
Real Estate (VNQ) 21.3% 15.2% 1.07 23.2%
Bitcoin (BTCUSD) -4.3% 43.7% 0.02 13.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
							Based On 5-Year Data
 Annualized
Return Annualized
Volatility Sharpe
Ratio Correlation
with AGIO
AGIO -9.6% 57.3% 0.07 -
Sector ETF (XLV) 6.3% 14.6% 0.25 32.5%
Equity (SPY) 11.1% 17.0% 0.50 36.0%
Gold (GLD) 22.1% 17.8% 1.02 6.5%
Commodities (DBC) 11.8% 18.8% 0.52 2.2%
Real Estate (VNQ) 3.7% 18.8% 0.10 30.8%
Bitcoin (BTCUSD) 4.3% 56.5% 0.30 18.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
							Based On 10-Year Data
 Annualized
Return Annualized
Volatility Sharpe
Ratio Correlation
with AGIO
AGIO -2.3% 57.3% 0.21 -
Sector ETF (XLV) 9.8% 16.5% 0.48 37.7%
Equity (SPY) 13.8% 17.9% 0.66 37.5%
Gold (GLD) 14.2% 15.9% 0.74 3.1%
Commodities (DBC) 8.6% 17.6% 0.41 11.0%
Real Estate (VNQ) 5.1% 20.7% 0.22 25.5%
Bitcoin (BTCUSD) 67.6% 66.9% 1.07 10.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
						
					
				
			
		
		
			
				
				 Short Interest
Short Interest: As Of Date 3312026
Short Interest: Shares Quantity 6.6 Mil
Short Interest: % Change Since 3152026 6.7%
Average Daily Volume 1.0 Mil
Days-to-Cover Short Interest 6.4 days
Basic Shares Quantity 58.3 Mil
Short % of Basic Shares 11.3%
			
		
	

	
		
			
				 Returns Analyses
 Title
0 Would You Still Hold Agios Pharmaceuticals Stock If It Fell Another 30%?
			
		
	

	
		
			
				
				 Earnings Returns History
				Expand for More  Forward Returns
Earnings Date 1D Returns 5D Returns 21D Returns
2/12/2026 1.3% 3.1% 0.5%
10/30/2025 2.9% -3.5% -33.7%
7/31/2025 -0.9% 0.5% 1.7%
5/1/2025 4.2% -5.0% 8.1%
2/13/2025 1.5% 2.9% -5.7%
10/31/2024 -4.0% 11.4% 28.3%
8/1/2024 -4.1% -8.3% -1.2%
5/2/2024 2.7% -3.6% 8.0%
... 
SUMMARY STATS      
# Positive 10 11 14
# Negative 13 12 9
Median Positive 3.2% 5.6% 8.1%
Median Negative -3.9% -7.6% -17.1%
Max Positive 14.7% 17.1% 28.3%
Max Negative -5.5% -15.1% -33.7%
				Collapse to Preview  Forward Returns
Earnings Date 1D Returns 5D Returns 21D Returns
2/12/2026 1.3% 3.1% 0.5%
10/30/2025 2.9% -3.5% -33.7%
7/31/2025 -0.9% 0.5% 1.7%
5/1/2025 4.2% -5.0% 8.1%
2/13/2025 1.5% 2.9% -5.7%
10/31/2024 -4.0% 11.4% 28.3%
8/1/2024 -4.1% -8.3% -1.2%
5/2/2024 2.7% -3.6% 8.0%
2/15/2024 3.5% 15.0% 15.6%
11/2/2023 -1.4% 5.6% 7.5%
8/3/2023 -0.2% 0.3% 5.6%
5/4/2023 7.7% 12.8% 13.9%
2/23/2023 -1.7% -5.7% -17.1%
11/3/2022 -5.2% -5.4% 13.3%
8/4/2022 14.7% 13.1% 22.6%
5/5/2022 -4.7% -15.1% -18.5%
2/24/2022 5.7% 17.1% 8.0%
11/3/2021 -0.3% -12.6% -30.0%
7/29/2021 -0.3% -6.9% -12.1%
2/25/2021 -4.9% -12.8% -6.6%
11/5/2020 1.3% 0.2% 7.7%
7/30/2020 -3.9% -12.3% -20.6%
4/30/2020 -5.5% -10.9% 18.8%
SUMMARY STATS      
# Positive 10 11 14
# Negative 13 12 9
Median Positive 3.2% 5.6% 8.1%
Median Negative -3.9% -7.6% -17.1%
Max Positive 14.7% 17.1% 28.3%
Max Negative -5.5% -15.1% -33.7%
			
		
		
			
				
				 SEC Filings
				Expand for MoreReport Date Filing Date Filing
12/31/2025 02/12/2026 10-K
09/30/2025 10/30/2025 10-Q
06/30/2025 07/31/2025 10-Q
03/31/2025 05/01/2025 10-Q
12/31/2024 02/13/2025 10-K
09/30/2024 10/31/2024 10-Q
06/30/2024 08/01/2024 10-Q
03/31/2024 05/02/2024 10-Q
12/31/2023 02/15/2024 10-K
09/30/2023 11/02/2023 10-Q
06/30/2023 08/03/2023 10-Q
03/31/2023 05/04/2023 10-Q
12/31/2022 02/23/2023 10-K
09/30/2022 11/03/2022 10-Q
06/30/2022 08/04/2022 10-Q
03/31/2022 05/05/2022 10-Q
				Collapse to PreviewReport Date Filing Date Filing
12/31/2025 02/12/2026 10-K
09/30/2025 10/30/2025 10-Q
06/30/2025 07/31/2025 10-Q
03/31/2025 05/01/2025 10-Q
12/31/2024 02/13/2025 10-K
09/30/2024 10/31/2024 10-Q
06/30/2024 08/01/2024 10-Q
03/31/2024 05/02/2024 10-Q
12/31/2023 02/15/2024 10-K
09/30/2023 11/02/2023 10-Q
06/30/2023 08/03/2023 10-Q
03/31/2023 05/04/2023 10-Q
12/31/2022 02/23/2023 10-K
09/30/2022 11/03/2022 10-Q
06/30/2022 08/04/2022 10-Q
03/31/2022 05/05/2022 10-Q
12/31/2021 02/24/2022 10-K
09/30/2021 11/03/2021 10-Q
06/30/2021 07/29/2021 10-Q
03/31/2021 04/29/2021 10-Q
12/31/2020 02/25/2021 10-K
09/30/2020 11/05/2020 10-Q
06/30/2020 07/30/2020 10-Q
03/31/2020 04/30/2020 10-Q
12/31/2019 02/19/2020 10-K
09/30/2019 10/31/2019 10-Q
06/30/2019 08/01/2019 10-Q
03/31/2019 05/02/2019 10-Q
			
		
	

	
		
			
				
				 Recent Forward Guidance [BETA]
				Latest: Q4 2025 Earnings Reported 2/12/2026
				Forward Guidance Guidance Change
Metric Low Mid High % Chg % Delta Change Prior
Q1 2026 Pre-sNDA meeting with FDA for mitapivat in sickle cell disease             
2026 Topline results for Phase 2 tebapivat trial in sickle cell disease             
				Prior: Q3 2025 Earnings Reported 10/30/2025
				Forward Guidance Guidance Change
Metric Low Mid High % Chg % Delta Change Prior
2025 RISE UP Phase 3 trial topline results             
2026 European Commission decision on PYRUKYND             
2026 Phase 2b tebapivat trial topline results             
			
		
	

	
		
			
				
				 Insider Activity
				Expand for More# Owner Title Holding Action Filing Date Price Shares Transacted
Value Value of
Held Shares Form
1 Burns, James William Chief Legal Officer Direct Sell 1022026 27.09 2,932 79,428 859,241 Form
2 Goff, Brian Chief Executive Officer Direct Sell 1022026 27.09 18,703 506,664 3,700,033 Form
3 Gheuens, Sarah Chief Medical Officer Direct Sell 1022026 27.09 2,932 79,428 1,755,297 Form
4 Milanova, Tsveta Chief Commercial Officer Direct Sell 1022026 27.09 2,932 79,428 790,757 Form
5 Jones, Cecilia Chief Financial Officer Direct Sell 1022026 27.09 2,932 79,428 1,013,003 Form
				Collapse to Preview# Owner Title Holding Action Filing Date Price Shares Transacted
Value Value of
Held Shares Form
1 Burns, James William Chief Legal Officer Direct Sell 1022026 27.09 2,932 79,428 859,241 Form
2 Goff, Brian Chief Executive Officer Direct Sell 1022026 27.09 18,703 506,664 3,700,033 Form
3 Gheuens, Sarah Chief Medical Officer Direct Sell 1022026 27.09 2,932 79,428 1,755,297 Form
4 Milanova, Tsveta Chief Commercial Officer Direct Sell 1022026 27.09 2,932 79,428 790,757 Form
5 Jones, Cecilia Chief Financial Officer Direct Sell 1022026 27.09 2,932 79,428 1,013,003 Form
6 Scadden, David   Direct Sell 11142025 43.84 200 8,768 771,716 Form
7 Gheuens, Sarah Chief Medical Officer Direct Sell 11132025 43.78 2,454 107,436 2,702,408 Form
8 Gheuens, Sarah Chief Medical Officer Direct Sell 11032025 43.81 200 8,762 2,704,260 Form
9 Gheuens, Sarah Chief Medical Officer Direct Sell 10292025 43.92 3,302 145,024 2,711,050 Form
10 Scadden, David   Direct Sell 10102025 41.00 200 8,200 721,723 Form
11 Scadden, David   Direct Sell 10022025 40.00 200 8,000 704,120 Form
12 Jones, Cecilia Chief Financial Officer Direct Sell 9302025 36.77 3,651 134,247 1,245,400 Form
13 Washburn, Theodore James Jr Principal Accounting Officer Direct Sell 9092025 36.87 8,546 315,091 32,003 Form
14 Scadden, David   Direct Sell 8292025 40.00 200 8,000 704,120 Form
15 Goff, Brian Chief Executive Officer Direct Sell 8122025 36.67 11,085 406,487 4,529,772 Form
16 Scadden, David   Direct Sell 7152025 40.00 1,400 56,000 704,120 Form
17 Gheuens, Sarah Chief Medical Officer Direct Sell 7112025 37.99 11,914 452,601 2,327,624 Form
18 Gheuens, Sarah Chief Medical Officer Direct Sell 7032025 34.17 4,091 139,789 2,093,630 Form
19 Burns, James William Chief Legal Officer Direct Sell 6262025 33.54 2,799 93,878 960,921 Form
20 Gheuens, Sarah Chief Medical Officer Direct Sell 6262025 33.54 2,909 97,568 1,911,378 Form
21 Jones, Cecilia Chief Financial Officer Direct Sell 6262025 33.54 1,780 59,701 1,007,843 Form
22 Milanova, Tsveta Chief Commercial Officer Direct Sell 6262025 33.54 2,770 92,906 876,132 Form
23 Goff, Brian Chief Executive Officer Direct Sell 6262025 33.54 18,700 627,198 3,535,150 Form
24 Fouse, Jacqualyn A Direct Sell 4102025 25.90 7,497 194,172 3,864,798 Form
25 Goff, Brian Chief Executive Officer Direct Sell 3032026 28.96 18,055 522,873 4,278,348 Form
26 Burns, James William Chief Legal Officer Direct Sell 3032026 28.96 5,218 151,113 1,000,018 Form
27 Gheuens, Sarah Chief Medical Officer Direct Sell 3032026 28.96 4,055 117,433 1,957,928 Form
28 Jones, Cecilia Chief Financial Officer Direct Sell 3032026 28.96 5,035 145,814 1,123,648 Form
29 Milanova, Tsveta Chief Commercial Officer Direct Sell 3032026 28.96 2,868 83,057 1,123,011 Form
30 Washburn, Theodore James Jr Principal Accounting Officer Direct Sell 3032026 28.96 2,223 64,378 75,151 Form
31 Washburn, Theodore James Jr Principal Accounting Officer Direct Sell 3052026 28.88 5,272 152,255 25,068 Form
32 Viswanadhan, Krishnan Chief Corp Dev & Strategy Direct Sell 3092026 27.80 2,959 82,260 142,920 Form
33 Burns, James William Chief Legal Officer Direct Sell 4062026 34.71 3,280 113,849 1,711,411 Form
34 Gheuens, Sarah Chief Medical Officer Direct Sell 4062026 34.71 2,940 102,047 2,786,415 Form
35 Jones, Cecilia Chief Financial Officer Direct Sell 4062026 34.71 3,141 109,024 1,908,981 Form
36 Milanova, Tsveta Chief Commercial Officer Direct Sell 4062026 34.71 3,262 113,224 1,625,435 Form
37 Viswanadhan, Krishnan Chief Corp Dev & Strategy Direct Sell 4062026 34.71 2,959 102,707 356,888 Form
38 Goff, Brian Chief Executive Officer Direct Sell 4062026 34.71 19,068 661,850 6,164,635 Form
			
		
	
	
	
		
			
				
				 AGIO Trade Sentinel
				
				
					
						
					
					
						
					
					
						
					
					
						
					
				
				
				
				
				
					
						
							
								
									
										Stock Conviction									
										null
									
								
								
									 
									 	CONVICTION RATIONALE
										null
									 
								
								
									
										
											STOCK ARCHETYPE
											null
										
										null
									
								
							

							
								
									
										INVESTMENT THESIS
										null
										null
										
										
											Mechanism:
											null
										
										
										
											Supporting Evidence:
											
												
											
										
									
								
								
								
									
										PRIMARY RISK
										null
										null
										
										 
											Mechanism:
											null
										
										
										
											Supporting Evidence:
											
												 
											
										
									
								
							

							
								 Key KPI Watchlist
								 
									
										
											
												
													KPI
													Threshold
													Rationale
												
											
											
												
											
										
									
								 
							

						
					

					
						
							
								Core Investment Debate
								
							

							
								
									
										BULL VIEW
										
									
								
								
									
										CORE TENSION
										
										
										PREVAILING SENTIMENT
										
										
									
								
								
									
										BEAR VIEW
										
									
								
							

							
								Next 6 months: Risks and Catalysts
								
									
										
											
												
													Timeline
													Event & Metric To Watch
												
											
											
												
											
										
									
								
							

							
								Key Events in Last 6 Months
								
									
										
											
												
													Date
													Event
													Stock Impact
												
											
											
												
											
										
									
								
							

							
								Risk Management
								
									
										
											 Position Sizing
											null
											null
											null
										
										
											 Diversification Alternatives
											
												
											
										
									
								
							
						
					

					
						
							How Is The Market Pricing AGIO?

							
								
									
								
							

							
								
									
								
							

							
								
									
										 What will confirm the thesis
										
									
								

								
									
										 What will damage the thesis
										
									
								

								
									
										 Noise: Real but irrelevant to thesis
										
									
								
							

							
								Repricing Catalyst
								
							

							
								What AGIO Makes & Who Pays

								
									
										TTM figures based on 
									
								
								
								
									
								
							

							
								AGIO Evolution: Price Return by Era
								
								
								

								
									
										
									
								
							

						
					

					
						
						
							
							
								
								

								
									
										① Structure
										
											0
											
										
										
									
									
										② Volume / Momentum
										
											0
											
										
										
									
									
										③ Catalyst
										
											0
											
										
										
									
								

								
									Combined Score
									
										
									
									0 / 12
								
							

							
								
									1
									Price Structure & Trend
									 · 
									▾
								
								
									
										▲
										
									

									
										
											Current
											$
											
											
										
										
											20D SMA
											$
											
											Below
										
										
											50D SMA
											$
											Slope: %
											Below
										
										
											200D SMA
											$
											Slope: %
											Below
										
									

									
										✕
										 —  trading days ago
									

									
										
											52W High
											$
										
										
											From 52W High
											%
										
										
											All-Time High
											$
										
										
											From ATH
											%
										
									
									
										
											52W Low
											$
										
										
											From 52W Low
											%
										
									
								
							

							
								
									2
									Momentum
									
									▾
								
								
									
										↑
										
									

									
										
											5D
											%
											
										
										
											20D
											%
											
										
										
											63D
											%
											
										
										
											126D
											%
											
										
										
											252D
											%
											
										
									
								
							

							
								
									3
									Relative Strength vs. SPY
									
									▾
								
								
									
										↑
										
									

									
										
											20D
											
											%
										
										
											63D
											
											%
										
										
											126D
											
											%
										
										
											252D
											
											%
										
									

									
										
											RS Trend
											%
										
										
											RS Character
											
										
									
								
							

							
								
									4
									Institutional Footprint & Volume
									
									▾
								
								
									
										↓
										
									
									
										◈
										
									

									
										
											Score
											
										
										
											Up/Down Vol 20D
											
										
										
											Up/Down Vol 60D
											
										
									
									
										
											OBV Slope 20D
											
										
										
											OBV Slope 60D
											
										
										
											Hi-Conv Up Days
											
											Past 60D
										
										
											Hi-Conv Down Days
											
											Past 60D
										
									
									
										
											Volume Trend
											
											20D avg vs 60D avg
										
										
									
								
							

							
								
									5
									Volatility
									
									▾
								
								
									
										≈
										
									
									
										
											HV 20D
											%
										
										
											HV 60D
											%
										
										
											HV 252D
											%
										
									
									
										
											Compression Ratio
											
										
										
											ATR 14D
											%
										
									
								
							

							
								
									6
									Key Price Levels
									Range · Vol 
									▾
								
								
									
										◈
										
									
									
										
											Nearest Resistance
											$
											% away ·  touches
										
										
											Nearest Support
											$
											% away ·  touches
										
										
											2nd Support
											$
											 touches
										
										
											Risk / Reward
											×
										
									
									
										
											Approach Volume
											
										
										
											Current Price
											$
										
									
								
							

							
								
									7
									Earnings Reaction History
									
									▾
								
								
									
										★
										
									
									
										
											
												
												
											
											
												%
												Earnings Day Return · Vol Spike ×
												
													
														5D
														%
													
													
														10D
														%
													
													
														20D
														%
													
													
														Post Vol
														×
													
												
												
												
											
										
										
											
												
												
											
											
												%
												Earnings Day Return · Vol Spike ×
												
													
														5D
														%
													
													
														10D
														%
													
													
														20D
														%
													
													
														Post Vol
														×
													
												
												
												
											
										
									
								
							

							
								
									8
									How the Verdict Is Derived
									Three Pillars
									▾
								
								
									
										
											
												Pillar
												Score
											
										
										
											
												① Structure
												0
											
											
												② Vol / Mom
												0
											
											
												③ Catalyst
												0
											
										
									
									
										ℹ
										
											Bull Pillars: 0 ·
											Bear Pillars: 0 ·
											Combined Score: 0 →
											
										
									
								
							

							
								Price Intelligence is derived from price-volume pattern analysis only. All moving averages are simple (SMA). Relative strength benchmarked against SPY.
							
						
					
					
				
			
		
	
	
	
		
			
				
				 Industry Resources
Health Care Resources
U.S. National Library of Medicine
ClinicalTrials.gov
Modern Healthcare
Healthcare Dive
Fierce Healthcare
Health Affairs
Health Data Management
FDA Tracker
Biotechnology Resources
Fierce Biotech
Nature Biotechnology
Genetic Engineering & Biotechnology News
Biotechnology Innovation Organization
BioWorld
BioTechniques
HBS Biotechnology Publications
			
		
		
			
				
				 External Quote Links
0 Y Finance Barrons
1 TradingView Morningstar
2 SeekingAlpha ValueLine
3 Motley Fool Robinhood
4 CNBC Etrade
5 MarketWatch Unusual Whales
6 YCharts Perplexity Finance
7 FinViz  

Prefer one of these to Trefis? Tell us why.

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

	Title	Date
0	DASHBOARDS
1	Agios Stock (+19%): AQVESME Thalassemia Approval Ignites Re-Rate	12/25/2025
2	Agios Pharmaceuticals Earnings Notes	12/16/2025
3	Would You Still Hold Agios Pharmaceuticals Stock If It Fell Another 30%?	10/17/2025
4	Does Agios Pharmaceuticals Stock Lead the Pack?	08/13/2025
5	Why Agios Pharmaceuticals Stock Moved: AGIO Stock Has Lost 26% Since 2021 Fiscal End, Primarily Due To Unfavorable Change In Price To Sales Multiple (P/S)	08/08/2025
6	AGIO Dip Buy Analysis	07/10/2025
7	Agios Pharmaceuticals Stock Falls 10% In A Single Week, Now Is Not The Time To Buy The Stock	05/16/2025
8	Agios Pharmaceuticals (AGIO) Valuation Ratios Comparison	05/15/2025
9	Agios Pharmaceuticals Total Shareholder Return (TSR): 47.6% in 2024 and 0.0% 3-yr compounded annual returns (below peer average)	03/07/2025
10	Agios Pharmaceuticals (AGIO) Operating Cash Flow Comparison	02/17/2025
11	ARTICLES
12	Market Movers \| Winners: WSHP, SGBX, SEMR \| Losers: IVP, AGIO, TPST	11/20/2025

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03312026	PGNY	Progyny	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	CNC	Centene	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	OSCR	Oscar Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.0%	3.0%	-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper	03202026	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.4%	-0.4%	-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%	03202026	GILD	Gilead Sciences	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	1.6%	1.6%	-2.2%

	AGIO	VRTX	CRSP	BMRN	ALNY	IONS	Median
Name	Agios Ph.	Vertex P.	CRISPR T.	BioMarin.	Alnylam .	Ionis Ph.
Mkt Price	32.93	436.68	51.28	54.52	322.11	75.26	64.89
Mkt Cap	1.9	110.7	4.9	10.5	42.6	12.2	11.4
Rev LTM	54	12,001	0	3,221	3,714	944	2,082
Op Inc LTM	-472	4,554	-665	409	502	-382	14
FCF LTM	-387	3,194	-371	717	465	-326	70
FCF 3Y Avg	-364	1,832	-263	415	155	-405	-54
CFO LTM	-373	3,631	-345	828	524	-269	128
CFO 3Y Avg	-353	2,225	-249	520	207	-359	-21

					Post-Approval Fwd Returns
FDA App #	Brand Name	Generic Name	Dosage Form	FDA Approval	3M Rtn	6M Rtn	1Y Rtn	2Y Rtn	Total Rtn
NDA216196	PYRUKYND	mitapivat sulfate	tablet	2172022	-30.0%	-11.2%	-6.0%	-10.0%	11.7%

$ Mil	2025	2024	2021
Product revenue, net	27	12	60
Milestone revenue	0	2
Collaboration revenue – other			11
Collaboration revenue – related party			39
Royalty revenue – related party			8
Total	27	14	118

Market Price	$32.92
Market Cap ($ Bil)	1.9
First Trading Date	07/24/2013
Distance from 52W High	-27.6%
	50 Days	200 Days
DMA Price	$29.29	$33.76
DMA Trend	indeterminate	up
Distance from DMA	12.4%	-2.5%
	3M	1YR
Volatility	44.2%	70.1%
Downside Capture	0.02	0.32
Upside Capture	114.99	70.65
Correlation (SPY)	21.9%	17.9%

	1M	2M	3M	6M	1Y	3Y
Beta	1.35	0.79	0.77	0.66	0.88	1.06
Up Beta	4.69	1.16	1.59	2.48	0.96	0.91
Down Beta	0.09	0.75	0.49	0.08	0.81	0.78
Up Capture	185%	115%	112%	-13%	56%	171%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	10	21	30	63	131	373
Down Capture	86%	23%	37%	60%	87%	107%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	12	21	33	63	120	374

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AGIO
AGIO	34.9%	70.4%	0.82	-
Sector ETF (XLV)	12.3%	16.8%	0.52	27.4%
Equity (SPY)	31.2%	17.3%	1.47	21.3%
Gold (GLD)	60.1%	27.8%	1.69	4.0%
Commodities (DBC)	29.8%	16.6%	1.58	7.6%
Real Estate (VNQ)	21.3%	15.2%	1.07	23.2%
Bitcoin (BTCUSD)	-4.3%	43.7%	0.02	13.9%

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AGIO
AGIO	-9.6%	57.3%	0.07	-
Sector ETF (XLV)	6.3%	14.6%	0.25	32.5%
Equity (SPY)	11.1%	17.0%	0.50	36.0%
Gold (GLD)	22.1%	17.8%	1.02	6.5%
Commodities (DBC)	11.8%	18.8%	0.52	2.2%
Real Estate (VNQ)	3.7%	18.8%	0.10	30.8%
Bitcoin (BTCUSD)	4.3%	56.5%	0.30	18.0%

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with AGIO
AGIO	-2.3%	57.3%	0.21	-
Sector ETF (XLV)	9.8%	16.5%	0.48	37.7%
Equity (SPY)	13.8%	17.9%	0.66	37.5%
Gold (GLD)	14.2%	15.9%	0.74	3.1%
Commodities (DBC)	8.6%	17.6%	0.41	11.0%
Real Estate (VNQ)	5.1%	20.7%	0.22	25.5%
Bitcoin (BTCUSD)	67.6%	66.9%	1.07	10.1%

Short Interest: As Of Date	3312026
Short Interest: Shares Quantity	6.6 Mil
Short Interest: % Change Since 3152026	6.7%
Average Daily Volume	1.0 Mil
Days-to-Cover Short Interest	6.4 days
Basic Shares Quantity	58.3 Mil
Short % of Basic Shares	11.3%

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
2/12/2026	1.3%	3.1%	0.5%
10/30/2025	2.9%	-3.5%	-33.7%
7/31/2025	-0.9%	0.5%	1.7%
5/1/2025	4.2%	-5.0%	8.1%
2/13/2025	1.5%	2.9%	-5.7%
10/31/2024	-4.0%	11.4%	28.3%
8/1/2024	-4.1%	-8.3%	-1.2%
5/2/2024	2.7%	-3.6%	8.0%
...
SUMMARY STATS
# Positive	10	11	14
# Negative	13	12	9
Median Positive	3.2%	5.6%	8.1%
Median Negative	-3.9%	-7.6%	-17.1%
Max Positive	14.7%	17.1%	28.3%
Max Negative	-5.5%	-15.1%	-33.7%

Report Date	Filing Date	Filing
12/31/2025	02/12/2026	10-K
09/30/2025	10/30/2025	10-Q
06/30/2025	07/31/2025	10-Q
03/31/2025	05/01/2025	10-Q
12/31/2024	02/13/2025	10-K
09/30/2024	10/31/2024	10-Q
06/30/2024	08/01/2024	10-Q
03/31/2024	05/02/2024	10-Q
12/31/2023	02/15/2024	10-K
09/30/2023	11/02/2023	10-Q
06/30/2023	08/03/2023	10-Q
03/31/2023	05/04/2023	10-Q
12/31/2022	02/23/2023	10-K
09/30/2022	11/03/2022	10-Q
06/30/2022	08/04/2022	10-Q
03/31/2022	05/05/2022	10-Q

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
Q1 2026 Pre-sNDA meeting with FDA for mitapivat in sickle cell disease
2026 Topline results for Phase 2 tebapivat trial in sickle cell disease

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Burns, James William	Chief Legal Officer	Direct	Sell	1022026	27.09	2,932	79,428	859,241	Form
2	Goff, Brian	Chief Executive Officer	Direct	Sell	1022026	27.09	18,703	506,664	3,700,033	Form
3	Gheuens, Sarah	Chief Medical Officer	Direct	Sell	1022026	27.09	2,932	79,428	1,755,297	Form
4	Milanova, Tsveta	Chief Commercial Officer	Direct	Sell	1022026	27.09	2,932	79,428	790,757	Form
5	Jones, Cecilia	Chief Financial Officer	Direct	Sell	1022026	27.09	2,932	79,428	1,013,003	Form

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Agios Pharmaceuticals (AGIO)

Market Price (4/12/2026): $32.93 | Market Cap: $1.9 BilSector: Health Care | Industry: Biotechnology

Agios Pharmaceuticals (AGIO)

Market Price (4/12/2026): $32.93Market Cap: $1.9 BilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Agios Pharmaceuticals (AGIO)

Key Business Risks for Agios Pharmaceuticals (AGIO)

Expected Drivers of Future Revenue Growth for Agios Pharmaceuticals (AGIO)

Share Repurchases

Share Issuance

Inbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets vs. Agios Pharmaceuticals (AGIO)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for AGIO: 57.5% | 35.6x)

Higher Rev Chg LTM (Value for AGIO: 48.0%)

Higher Rev Chg 3Y Avg (Value for AGIO: 57.5%)

Higher Op Mgn LTM (Value for AGIO: -873.9%)

Higher CFO/Rev LTM (Value for AGIO: -690.3%)

Higher FCF/Rev LTM (Value for AGIO: -716.8%)

Higher Total Yield (Value for AGIO: -21.5%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for AGIO: 57.5% | 35.6x)

Higher Rev Chg LTM (Value for AGIO: 48.0%)

Higher Rev Chg 3Y Avg (Value for AGIO: 57.5%)

Higher Op Mgn LTM (Value for AGIO: -873.9%)

Higher CFO/Rev LTM (Value for AGIO: -690.3%)

Higher FCF/Rev LTM (Value for AGIO: -716.8%)

Higher Total Yield (Value for AGIO: -21.5%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for AGIO: 57.5% | 35.6x)

Higher Rev Chg LTM (Value for AGIO: 48.0%)

Higher Rev Chg 3Y Avg (Value for AGIO: 57.5%)

Higher Op Mgn LTM (Value for AGIO: -873.9%)

Higher CFO/Rev LTM (Value for AGIO: -690.3%)

Higher FCF/Rev LTM (Value for AGIO: -716.8%)

Higher Total Yield (Value for AGIO: -21.5%)

Best Bets in Health Care

P/EBIT (Value for AGIO: -4.1x)

P/E (Value for AGIO: -4.7x)

Rev Chg 3Y Avg (Value for AGIO: 57.5%)

Rev Chg LTM (Value for AGIO: 48.0%)

Rev Chg Q (Value for AGIO: 86.1%)

FCF/Rev 3Y Avg (Value for AGIO: -987.4%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Market Price (4/12/2026): $32.93 | Market Cap: $1.9 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (4/12/2026): $32.93
Market Cap: $1.9 Bil
Sector: Health Care
Industry: Biotechnology